Laparoscopic nephrectomy is both operatively and oncologically safe in T-1 and T-2 disease, and although technically more demanding, it is also safe in selected T-3 disease.”
“Recently, aqueous solutions polluted

by BPA have been bioremediated by us using laccase immobilized on hydrophobic membranes in non-isothermal bioreactors. BPA degradation was checked using analytical methods. To assess in vitro the occurred bioremediation, the proliferation and viability indexes of MCF-7 cells incubated in the presence of aqueous solutions of BPA, or of enzyme-treated BPA solutions, have been measured as a function of the initial BPA concentration. The results demonstrated that:

i) at each initial BPA concentration used, both the proliferation and viability indexes are a function of the duration of enzyme treatment:

ii) proliferation and Selleck Rigosertib viability are uncoupled biological processes with respect to BPA enzyme treatment.

Non-isothermal bioreactors are a useful tool for the bioremediation of aqueous solutions polluted by BPA, which is an example of an endocrine disruptor that belongs to the alkyl phenol family. (C) 2008 Elsevier Ltd. All rights reserved.”
“Clinical symptoms in lumbar degenerative spondylolisthesis (LDS) vary from predominantly radiating pain to severe mechanical low back pain. We examined whether the outcome of surgery

for LDS varied depending on the predominant baseline symptom and the treatment administered [decompression with fusion (D&F) or decompression BIIB057 clinical trial alone (D)].

213 consecutive patients (69 +/- A 9 years; 155f, 58 m) participated. Inclusion criteria were LDS, maximum three affected levels, no previous surgery at the affected level, and D (N = 56) or D&F (N = 157) as the operative procedure. Pre-op and at 12 months’ follow-up Selleckchem Rigosertib (FU), patients completed the multidimensional Core Outcome Measures Index (COMI) including 0-10 leg-pain (LP)

and LBP scales. At 12 months’ FU, patients rated global outcome which was then dichotomised into “”good”" and “”poor”".

Pre-operatively, LBP and COMI scores were significantly worse (p < 0.05) in the D&F group than in the D group. The improvement in COMI at 12 months’ FU was significantly greater for D&F than for D (p < 0.001) and was not influenced by the patient’s declared “”main problem”" at baseline (back pain, leg pain, or neurological disturbances) (p > 0.05). There was a higher proportion (p = 0.01) of “”good”" outcomes at 12 months’ FU in D&F (86%) than in D (70%). Multiple regression analysis, controlling for possible confounders, revealed treatment group to be the only significant predictor of outcome (adding fusion = better outcome).

Our study indicated that LDS patients showed better patient-based outcome with instrumented fusion and decompression than with decompression alone, regardless of baseline symptoms.